sorafenib has been researched along with Cirrhosis, Liver in 103 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (7.77) | 29.6817 |
| 2010's | 71 (68.93) | 24.3611 |
| 2020's | 24 (23.30) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Fang, L; Li, J; Li, L; Liu, G; Wei, C; Yuan, S; Zhang, L | 1 |
| Johnson, PJ; Kalyuzhnyy, A; Pinato, DJ; Toyoda, H | 1 |
| Nagasaki, Y; Nishikawa, Y; Tran, HT; Vong, LB | 1 |
| Chapin, WJ; Hwang, WT; Kaplan, DE; Karasic, TB; McCarthy, AM | 1 |
| Chen, XF; Ji, S | 1 |
| Fang, X; Gong, L; Guan, XY; Lam, KO; Lam, RHW; Lee, AW; Liu, B; Luo, J; Ren, J; Tiu, YC; Yan, Q; Yang, Y; Zhang, Y | 1 |
| Bi, J; Cao, Y; Li, J; Li, Y; Liang, Q; Liu, J; Liu, Y; Yang, J; Zhou, L | 1 |
| Allaire, M; Blaise, L; Campion, B; Cluzel, P; Evain, M; Ganne-Carrié, N; Giudicelli, H; Larrey, E; Rudler, M; Sultanik, P; Thabut, D; Wagner, M | 1 |
| Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A | 1 |
| Chen, B; Cheng, J; Lei, J; Li, Y; Lu, Y; Safadi, R; Si, T; Wu, T; Yang, X; Zhang, L; Zhang, R | 1 |
| He, J; Jia, Q; Li, R; Li, Y; Liu, Q; Tang, Q; Xiong, Y; Zhang, J | 1 |
| Akahane, T; Douhara, A; Furukawa, M; Kaji, K; Kawaratani, H; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Saikawa, S; Sato, S; Sawada, Y; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H | 1 |
| Likhitsup, A; Parikh, ND | 1 |
| Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Abo Elseud, Y; Albarrak, J; Mohanty, A; Salamah, R; Shaaban, A | 1 |
| Aydin, C; Yilmaz, S | 1 |
| Barbisan, LF; Cogliati, B; Da Silva, TC; de Albuquerque Landi, MF; Morais, JÁ; Oliveira, CP; Romualdo, GR; Vinken, M | 1 |
| Armeli Iapichino, EC; Bramanti, A; Bramanti, P; Ciurleo, R; Fagone, P; Magro, GG; Mangano, K; Nicoletti, F; Pesce, A; Petralia, MC | 1 |
| Bonney, G; Chow, P; Dan, YY; Huang, DQ; Jumat, H; Kow, A; Lee, GH; Lim, SG; Lim, YT; Muthiah, MD; Pang, YH; Shridhar, I; Soon, G; Tan, WX; Wee, A; Zhou, L | 1 |
| Chen, P; Chung, RT; Dai, G; He, L; Hong, J; Hu, K; Jiang, Y; Li, J; Lin, W; Peng, S; Qu, C; Tu, M; Xie, P; Yuan, H; Zheng, D | 1 |
| Abdelghani, MB; Audemar, F; Blanc, JF; Bourgeois, V; Bronowicki, JP; Costentin, C; Deplanque, G; Edeline, J; Faroux, R; Khemissa, F; Locher, C; Mabile-Archambeaud, I; Manfredi, S; Monterymard, C; Obled, S; Perarnau, JM; Seitz, JF; Senellart, H; Villing, AL | 1 |
| Biswas, S; Ghose, S; Ghufran, SM; Sharma, S | 1 |
| Heo, J; Kim, AR; Kim, S; Lee, M; Lee, SY; Seo, HR; Shum, D; Song, Y | 1 |
| Chen, DS; Chen, KF; Chen, LJ; Chen, PJ; Hu, TC; Huang, KW; Huang, YJ; Jao, P; Kao, JH; Liu, CH; Liu, CJ; Shiau, CW; Su, TH; Tai, WT; Tseng, TC; Wu, YM; Yang, HC; Yang, NJ | 1 |
| Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N | 1 |
| Ballarin, R; Berretta, M; Di Benedetto, F; Guerrini, GP; Magistri, P; Pecchi, A; Tarantino, G | 1 |
| Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A | 1 |
| Edwards, RJ; Ghassabian, S; Gillani, TB; Murray, M; Rawling, T | 1 |
| Cheng, Y; Wang, B; Xu, J; Xu, W; Zheng, H; Zhu, Y | 1 |
| Dore, GJ; Gomaa, A; Waked, I; Waziry, R | 1 |
| Chen, Y; Dong, H; Liu, X; Ma, Z; Wang, L; Xia, D; Xiong, Y | 1 |
| Chen, A; Ding, H; Shao, J; Wang, L; Yao, Z; Zhang, F; Zhang, Z; Zheng, S | 1 |
| Dong, J; Gao, J; Huang, Y; Meng, X; Rong, Y; Shi, P; Wang, X; Wu, C | 1 |
| Li, J; Long, J; Wang, Z; Xiao, W; Zhang, H | 1 |
| Futsukaichi, Y; Kobayashi, S; Minemura, M; Nagata, K; Tajiri, K; Takahara, T; Yasuda, I; Yasumura, S | 1 |
| Amir, E; Frizziero, M; Hubner, RA; Knox, JJ; Lamarca, A; McNamara, MG; Nuttall, C; Pihlak, R; Slagter, AE; Tariq, N; Valle, JW | 1 |
| Amanuma, M; Daido, Y; Higai, K; Igarashi, Y; Kobayashi, K; Matsui, D; Matsui, T; Matsukiyo, Y; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Shinohara, M; Wakui, N; Yoshimine, N | 1 |
| Chen, KH; Huang, CC; Jeng, KS; Lin, CC; Lin, CK; Teng, CJ | 1 |
| Adeli, S; Ashabi, G; Nabavizadeh, F; Panahi, M; Samandari, H; Shafie Ardestani, M; Shafie, F | 1 |
| Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SH; Sulaiman, AS | 1 |
| Biasco, G; Brandi, G; Calzà, L; Caraceni, P; Cirignotta, F; de Rosa, F; Girolamo, SD; Ricci, CS; Tufoni, M | 1 |
| Vogel, W | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 1 |
| Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P | 1 |
| Deng, YR; Diehl, AM; Gershwin, ME; He, XS; Lian, ZX; Liu, CH; Liu, P; Lu, FT; Ma, HD; Tsuneyama, K; Wang, YH; Yang, W | 1 |
| Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N | 1 |
| Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX | 1 |
| Groothuis, GM; Olinga, P; Oosterhuis, D; Westra, IM | 1 |
| Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D | 1 |
| Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC | 1 |
| Albines, GS; Fernández-Molina, J; Fuentes-Martínez, N; Mesa, A; Pérez, R; Rodríguez, M; Varela, M | 1 |
| Artaza Varasa, T; de la Cruz Pérez, G; Gómez Rodríguez, R; González de Frutos, C; Muñoz López, D; Romero Gutiérrez, M; Ruano Díaz, L; Sánchez Ruano, JJ | 1 |
| Albares, MP; Berbegal, L; Blanes, MM; de León, FJ | 1 |
| Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP | 1 |
| Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N | 1 |
| Chen, DS; Chen, KF; Chen, PJ; Cheng, HR; Huang, HP; Jao, P; Jeng, YM; Kao, JH; Liu, CH; Liu, CJ; Shiau, CW; Su, TH; Tai, WT; Tseng, TC; Yang, HC | 1 |
| Chen, Y; Chiang, T; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC; Wan, D; Wang, L | 1 |
| Chen, X; Liu, C; Lu, Y; Miao, H; Tang, B; Wang, L; Xu, Q; Yang, Z | 1 |
| BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H | 1 |
| Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A | 1 |
| Chun, G; Dua, S; Hiensch, R; Meinhof, K; Nandedkar, D | 1 |
| Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK | 1 |
| Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG | 1 |
| Cai, X; Chen, J; Liang, X; Liang, Y; Lin, S; Ma, R; Zhu, L | 1 |
| Bellot, P; Llanos, L; Pérez-Mateo, M; Such, J; Zapater, P | 1 |
| Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T | 1 |
| Bosch, J; Fernandez, M; Garcia-Pras, E; Mejias, M; Miquel, R; Tiani, C | 1 |
| Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A | 1 |
| Clark, JW; Zhu, AX | 1 |
| Befeler, AS; Gogia, S | 1 |
| Bruix, J; Shah, VH | 1 |
| Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R | 1 |
| Cabrera, R; Nelson, DR | 1 |
| Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A | 1 |
| Saif, MW | 1 |
| Aracil, C; Bruix, J; Bustamante, J; de la Mata, M; Del Val, A; Matilla, A; Pascasio, JM; Pascual, S; Reig, M; Rodríguez, M; Turnes, J; Varela, M | 1 |
| Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP | 1 |
| Byrnes, A; Pancoast, JR; Rixe, O; Verma, S; Wang, SX | 1 |
| Hirose, R; Vagefi, PA | 1 |
| Gao, J; Jiang, H; Ma, J; Wang, Y; Zhang, D; Zhang, J | 1 |
| Bustamante, J; Castells, L; de La Mata, M; Delgado, M; Forner, A; Matilla, A; Moreno, JM; Reig, M; Varela, M | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Capria, A; Gianluigi, G; Romano, A; Sacco, R | 1 |
| Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L | 1 |
| Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O | 1 |
| Blechacz, B; Ehman, R; Glaser, K; Huebert, R; Lomberk, G; Masyuk, T; Patel, L; Ritman, E; Routray, C; Shah, V; Shergill, U; Thabut, D; Urrutia, R; Vercnocke, A | 1 |
| Abou-Alfa, GK; Carter, WD; Chan, SL; Chiorean, EG; Gutheil, JC; Holcombe, RF; Lin, CC; Melink, TJ; Mulcahy, MF; Patel, K; Tsao, CJ; Wilson, WR | 1 |
| Ballarin, R; Berretta, M; D'Amico, G; De Ruvo, N; Di Benedetto, F; Gerunda, GE; Iemmolo, RM; Tarantino, G | 1 |
| Ciampi Dopazo, JJ; de Artaza Varasa, T; de la Cruz Perez, G; Gómez Moreno, AZ; Gómez Rodríguez, R; González de Frutos, C; Lanciego Pérez, C; Romero Gutiérrez, M | 1 |
| Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W | 1 |
| Lachenmayer, A; Mínguez, B | 1 |
| Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F | 1 |
| Kudo, M | 1 |
| Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L | 1 |
| Bruix, J; Forner, A; Llovet, JM | 1 |
| George, J; Nguyen, V; van der Poorten, D | 1 |
| Spechler, SJ; Wang, DH; Xie, B | 1 |
| Espat, NJ; Falanga, V; Katz, SC; Kurniali, PC; O'Gara, K; Somasundar, P; Wang, LJ; Wang, X | 1 |
| Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T | 1 |
| Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N | 1 |
| Chou, H; Fiel, MI; Friedman, SL; Hong, F | 1 |
| Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W | 1 |
| Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R | 1 |
13 review(s) available for sorafenib and Cirrhosis, Liver
| Article | Year |
|---|---|
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Early Detection of Cancer; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Models, Economic; Practice Guidelines as Topic; Quality-Adjusted Life Years; Sorafenib; Ultrasonography | 2020 |
Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation?
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Embolization, Therapeutic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Portal Vein; Preoperative Care; Radiosurgery; Sorafenib; Venous Thrombosis | 2020 |
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Patient Selection; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib | 2017 |
Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Remission Induction; Sorafenib | 2019 |
Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Retrospective Studies; Severity of Illness Index; Sorafenib | 2018 |
Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
Topics: Animals; Cellular Microenvironment; Humans; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Eruptions; Female; Health Care Costs; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult | 2010 |
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Survival Rate; Tumor Microenvironment | 2011 |
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Management; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Ultrasonography | 2012 |
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoembolization, Therapeutic; Hand-Foot Syndrome; Hepatitis, Viral, Human; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib; Treatment Outcome | 2012 |
6 trial(s) available for sorafenib and Cirrhosis, Liver
| Article | Year |
|---|---|
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pravastatin; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Regional Blood Flow; Sorafenib; Survival Analysis | 2011 |
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Half-Life; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
84 other study(ies) available for sorafenib and Cirrhosis, Liver
| Article | Year |
|---|---|
Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway.
Topics: Actins; Amino Acid Transport System y+; Animals; Cell Line; Collagen Type I; Ferroptosis; Hepatic Stellate Cells; Hepatocytes; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Cirrhosis; Macrophages; Male; Mice, Inbred C57BL; Models, Biological; Protein Stability; Signal Transduction; Sorafenib | 2022 |
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2022 |
Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy.
Topics: Actins; Antioxidants; Endothelial Cells; Hepatic Stellate Cells; Humans; Liver; Liver Cirrhosis; Nanoparticles; Oxidation-Reduction; Polymers; Reactive Oxygen Species; Silicon Dioxide; Sorafenib | 2022 |
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation.
Topics: Animals; Carbon Tetrachloride; Liver; Liver Cirrhosis; Lysine; Male; Rats; Rats, Sprague-Dawley; Sorafenib | 2022 |
Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment.
Topics: Amino Acid Oxidoreductases; Collagen; Collagen Type I; Drug Resistance; Ecosystem; Fluorouracil; Humans; Integrins; Liver Cirrhosis; Liver Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein-Lysine 6-Oxidase; Receptor, Serotonin, 5-HT1A; rho-Associated Kinases; Sorafenib; Tumor Microenvironment | 2022 |
Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
Topics: Collagen; Collagenases; Cytokines; Extracellular Matrix; Fibrosis; Glycyrrhetinic Acid; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Micelles; Prodrugs; Prospective Studies; Sorafenib | 2022 |
A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Prospective Studies; Retrospective Studies; Sorafenib | 2022 |
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Sorafenib | 2022 |
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Risk Factors; Sorafenib | 2022 |
CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis.
Topics: Animals; Fibronectins; Hepatic Stellate Cells; Humans; Liposomes; Liver; Liver Cirrhosis; Mice; Polyethylene Glycols; Sorafenib | 2023 |
Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sorafenib | 2019 |
Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Diabetes Mellitus; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Obesity; Platelet Count; Prevalence; Prognosis; Proportional Hazards Models; Radiotherapy; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Rate | 2020 |
Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Kuwait; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Sorafenib; Treatment Outcome | 2021 |
Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Topics: Animals; Cell Line, Tumor; Cell Survival; Coculture Techniques; Fibrosis; Hepatic Stellate Cells; Hepatocytes; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2021 |
Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis.
Topics: Angiogenesis Inhibitors; Animals; Computer Simulation; Concanavalin A; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Hepatic Stellate Cells; Humans; Imatinib Mesylate; Liver; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Sorafenib | 2020 |
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thioacetamide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Microenvironment; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Inflammation Mediators; Liver Cirrhosis; Liver Neoplasms; Mice; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
Cytoplasmic vacuolation with endoplasmic reticulum stress directs sorafenib induced non-apoptotic cell death in hepatic stellate cells.
Topics: Calreticulin; Caspase Inhibitors; Cell Death; Cell Line; Cell Survival; Cytoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Heat-Shock Proteins; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Liver Diseases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; Sorafenib; Vacuoles; X-Box Binding Protein 1 | 2021 |
Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Colforsin; Drug Synergism; Epithelial-Mesenchymal Transition; Fibroblasts; Hep G2 Cells; Hepatic Stellate Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Cirrhosis; Liver Neoplasms; Small Molecule Libraries; Sorafenib; Spheroids, Cellular; Tretinoin; Tumor Microenvironment | 2021 |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
Topics: Animals; Apoptosis; Bile Ducts; Carbon Tetrachloride; Cell Line; Cell Proliferation; Disease Models, Animal; Hepatic Stellate Cells; Humans; Ligation; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mutation; Phenyl Ethers; Phenylurea Compounds; Protein Domains; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Rats; Sorafenib; STAT3 Transcription Factor | 2017 |
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; France; Hand-Foot Syndrome; Humans; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2017 |
Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib | 2018 |
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Female; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Liver Cirrhosis; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2018 |
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kupffer Cells; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Real-Time Polymerase Chain Reaction; Smad3 Protein; Sorafenib; Transforming Growth Factor beta1 | 2018 |
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis | 2018 |
Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice.
Topics: Actins; Animals; Collagen Type I; Collagen Type III; Female; Liver; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Praziquantel; Receptor, Platelet-Derived Growth Factor beta; Schistosoma japonicum; Schistosomiasis japonica; Sorafenib | 2018 |
Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Hepatocellular; Cell Death; Cells, Cultured; Chemical and Drug Induced Liver Injury; Collagen Type I, alpha 1 Chain; ELAV-Like Protein 1; Female; Hepatic Stellate Cells; Humans; Iron; Lipid Peroxidation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Retrospective Studies; Sorafenib | 2018 |
Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Proto-Oncogene Proteins c-yes; Sorafenib; Tumor Microenvironment | 2019 |
The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line; Drug Synergism; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice, Inbred BALB C; Neovascularization, Physiologic; Primary Cell Culture; Receptor, Transforming Growth Factor-beta Type II; Sorafenib; STAT3 Transcription Factor; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2018 |
Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Interferon-gamma; Interleukin-4; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Th2 Cells | 2019 |
Liver Transplantation After Downstagings of Ruptured Advanced Hepatocellular Carcinoma in Cirrhotic Liver: Is It Advisable? A Case Report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Patient Selection; San Francisco; Sorafenib; Treatment Outcome | 2019 |
Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats.
Topics: Animals; Ascites; Bile Ducts; Collagen; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Liberation; Ligation; Liver; Liver Cirrhosis; Male; Rats; Rats, Wistar; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A | 2019 |
Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Follow-Up Studies; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Indonesia; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Radiofrequency Ablation; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome | 2020 |
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
Topics: Aged; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Cognition Disorders; Electroencephalography; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mood Disorders; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Liver tumors and loco-regional therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Evidence-Based Medicine; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib | 2013 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Topics: Actins; Active Transport, Cell Nucleus; Animals; Carbon Tetrachloride; Cell Nucleus; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Gene Expression; Hepatocytes; Immunoblotting; Immunohistochemistry; Interleukin-6; Kinetics; Kupffer Cells; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; STAT3 Transcription Factor; Tissue Inhibitor of Metalloproteinase-1 | 2013 |
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Disease Models, Animal; Hepatocyte Growth Factor; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Receptors, Chemokine; Receptors, CXCR4; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sorafenib | 2014 |
Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.
Topics: Animals; Becaplermin; Benzamides; Benzylisoquinolines; Cinnamates; Collagen Type I; Connective Tissue Growth Factor; Depsides; Down-Regulation; Gene Expression; HSP47 Heat-Shock Proteins; Imatinib Mesylate; Liver; Liver Cirrhosis; Male; Models, Biological; Niacinamide; Organ Culture Techniques; Perindopril; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-sis; Pyridones; Pyrimidines; Rats; Rats, Wistar; Rosmarinic Acid; Sorafenib; Transforming Growth Factor beta1; Valproic Acid | 2014 |
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2016 |
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Viral; Severity of Illness Index; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2015 |
[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice].
Topics: Aged; Aged, 80 and over; Alcoholism; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Diabetes Complications; Ethanol; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Remission Induction; Sorafenib | 2015 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethanol; Fatal Outcome; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Needles; Neoplasm Seeding; Niacinamide; Phenylurea Compounds; Radiofrequency Therapy; Sclerosing Solutions; Skin Neoplasms; Sorafenib | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collagens; Glutathione Transferase; HSP90 Heat-Shock Proteins; Interleukin-10; Interleukin-6; Liver Cirrhosis; Matrix Metalloproteinase 9; Mitochondria, Liver; Niacinamide; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylurea Compounds; Polarography; Protein Kinase Inhibitors; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcription Factors | 2015 |
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome | 2015 |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
Topics: Animals; Cell Line; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; STAT3 Transcription Factor | 2015 |
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Topics: Animals; Carbon Tetrachloride; Drug Carriers; Human Umbilical Vein Endothelial Cells; Lactic Acid; Liver; Liver Cirrhosis; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Kinase Inhibitors; Sorafenib | 2016 |
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.
Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Cytokines; Dimethylnitrosamine; Drug Therapy, Combination; Gadolinium; Hepatic Stellate Cells; Hepatocytes; Hydroxyproline; Kupffer Cells; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib | 2015 |
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography; Remission Induction; Sorafenib; Treatment Outcome | 2015 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Polyethylene Glycols; Protein Precursors; Prothrombin; Recombinant Proteins; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Dyspnea; Embolization, Therapeutic; Hepatitis B virus; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Injury; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Radiation Exposure; Sorafenib; Ytterbium | 2016 |
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Databases, Factual; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Medicare; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; SEER Program; Sorafenib; Survival Rate; United States | 2017 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Topics: Animals; Benzenesulfonates; Collateral Circulation; Enteritis; Heme Oxygenase-1; Hepatitis; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Neovascularization, Physiologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Splanchnic Circulation | 2009 |
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Treating hepatocellular carcinoma without liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Antiangiogenic therapy: not just for cancer anymore?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension, Portal; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Cyclophosphamide; Doxorubicin; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Sorafenib | 2009 |
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Sorafenib | 2010 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Platelet Count; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thrombocytopenia | 2010 |
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Early Diagnosis; Embolization, Therapeutic; Female; Hemochromatosis; Hepatectomy; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mass Screening; Niacinamide; Obesity; Phenylurea Compounds; Prospective Studies; Pyridines; Registries; Retrospective Studies; Sorafenib; Spain; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib | 2010 |
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Topics: Animals; Apoptosis; Base Sequence; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cells, Cultured; Collagen Type I; DNA Primers; Down-Regulation; Hepatic Stellate Cells; Humans; In Vitro Techniques; Liver Cirrhosis; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sorafenib | 2010 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Drug Interactions; Drug Monitoring; Gastrointestinal Diseases; Humans; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiography; raf Kinases; Sorafenib; Spain | 2010 |
Complete response for advanced liver cancer during sorafenib therapy: case report.
Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2011 |
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.
Topics: Animals; Benzenesulfonates; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Mice; Niacinamide; Paracrine Communication; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib | 2011 |
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2012 |
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Early Detection of Cancer; Ethanol; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sclerotherapy; Sorafenib; Spain | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Pressure; Protein Kinase Inhibitors; Pyridines; Real-Time Polymerase Chain Reaction; Sorafenib; Syndrome; Treatment Outcome | 2012 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Liver Cirrhosis; Liver Neoplasms; Male; Maxillary Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2012 |
The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hepatectomy; Hepatocytes; Liver Cirrhosis; Liver Neoplasms; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Models, Animal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Young Adult | 2012 |
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Count; Female; Humans; Immunity; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells; Treatment Outcome | 2012 |
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; RNA; Sorafenib; Thioacetamide | 2013 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting | 2013 |
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |